Project Grant R21AG101652
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Institute on Aging awarded $654,506 to The Regents of The University of Colorado, doing business as University of Colorado-Denver, on September 1, 2026, under the Aging Research program (CFDA 93.866). The award funds research into glial-associated immune dysregulation in Alzheimer's disease pathology, specifically investigating how reactive astrocytes drive immune dysfunction, alter dendritic structure in the brain, and contribute to synaptic dysfunction and cognitive decline. The...
- The National Institute on Aging awarded The Regents Of The University Of Colorado, doing business as University Of Colorado-Denver, $1,390,204 on February 15, 2026, under the Aging Research program (CFDA 93.866) to conduct research on the interaction between systemic endothelial glycocalyx fragility and brain dysfunction in aged sepsis survivors. The project will investigate pathologic organ crosstalk between the systemic vasculature and brain following sepsis, with particular focus on...
- The National Institute on Aging awarded $442,485 to The Regents of the University of Colorado (doing business as University of Colorado-Denver) on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate selective vulnerability of the locus coeruleus and hypothalamus to herpes simplex virus type 1 infection in Alzheimer's disease progression. The research employs spatial transcriptomics and proteomics via the NanoString GeoMx DSP platform alongside in vivo electrophysiological...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded $249,000 to The Regents of The University of Colorado on July 1, 2026, under the Aging Research program (CFDA 93.866). The award funds research investigating how beta-amyloid accumulation impacts hypocretin neuron activity and subsequently disrupts sleep architecture in Alzheimer's disease. The research examines whether beta-amyloid accelerates death of hypocretin neurons...
- The National Institute on Aging awarded Colorado State University $808,980 under the Aging Research program (CFDA 93.866) on September 1, 2026, to develop quantile-focused statistical tools and multimodal analyses that identify nonlinear genetic variants and interactions shaping Alzheimer's disease risk and cellular pathogenesis across key brain cell states. The project will create a comprehensive, distribution-aware genetic architecture atlas and deliver four primary products: quantile-specific...
- The National Institute on Aging awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $783,984 on March 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a multisite randomized controlled trial of GAPcareAD, a brief emergency department intervention addressing fall-related care needs for persons living with dementia and their care partners. The intervention adapts the GAPCARE fall prevention program for patients with Alzheimer's...
- The National Institute on Aging awarded the University of Colorado-Denver $429,000 under the Aging Research program (CFDA 93.866) on September 1, 2026, to develop clinical decision support tools and implementation guidance for primary care clinicians and patients navigating Alzheimer's disease blood biomarker testing and diagnostic decision-making. The project, R21AG104791, addresses a gap in primary care capacity to diagnose Alzheimer's disease and incorporate newly FDA-approved blood...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
- The National Institute on Aging awarded The General Hospital Corporation (Massachusetts General Hospital) $438,587 on July 15, 2026, under the Aging Research program (CFDA 93.866) to develop and evaluate intranasal iron nanochelation therapy for Alzheimer's disease. The project optimizes epsilon-poly-L-lysine-based, deferoxamine-coated nanochelators for intranasal administration and determines their therapeutic efficacy in reducing iron accumulation, neuroinflammation, and cognitive deficits...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...